Philip Beer

Philip Beer is a physician scientist, cancer biologist and oncology drug developer. He started his professional career as a haematologist with over 16 years frontline healthcare experience including clinical haemato-oncology, pathology and molecular diagnostics. This was followed by 8 years in academic research in Cambridge, UK and Vancouver, Canada, focussed on the development of improved cancer models. For the last 11 years, Philip has worked in the oncology biopharma sector, focussed on biomarker discovery and early phase oncology drug development, leading scientific and clinical development of small molecule and antibody programmes. In addition to his biopharma roles, Philip sits on a molecular tumour board for patients who have exhausted standard of care therapies, and supports biomarker development projects through membership of the International Cancer Genome Consortium, the Indian Cancer Genome Atlas, and as the Chair of the Genomics Working Group at BIVDA, The British In Vitro Diagnostic Association.